EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry

Michelle Chee iD, Yet Hong Khor, Dan Jackson, Wendy Cooper, Jason D'Costa, Sally de Boer, Adrienne Edwards, Samantha Ellis iD, Eli Gabbay, Henry Gallagher, Ian Glaspole, Nicole Goh und 20 weitere

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70490 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Michelle Chee und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Sleep Medicine, Box Hill Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Registries, Idiopathic Pulmonary Fibrosis, Immunosuppressive Agents, Antifibrotic Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre of Research Excellence in Pulmonary Fibrosis, Australasian Interstitial Lung Disease Registry, Australian Idiopathic Pulmonary Fibrosis Registry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Real‐world evaluation of clinical characteristics and treatment profile of patients with idiopathic pulmonary fibrosis (IPF) is needed to establish areas for improvement according to evidence‐based recommendations. This study evaluated the clinical characteristics and treatment profile of patients with IPF from the Australasian ILD Registry (AILDR), comparing them to the Australian IPF Registry (AIPFR) cohort, to identify differences in baseline characteristics among IPF patients treated with antifibrotics and immunosuppressants.

Methods

Consecutive patients with IPF enrolled between May 2016 and December 2023 from the AILDR and data of patients enrolled in the AIPFR between 2012 and 2016 were included.

Results

A total of 842 and 647 patients with IPF were included from the AILDR and the AIPFR respectively. Both cohorts were male predominant (AILDR: 72.0%; AIPFR: 67.7%) of similar mean body mass index (AILDR: 29.2 ± 4.9 kg/m 2 ; AIPFR: 28.7 ± 4.8 kg/m 2 ). With regard to disease‐targeted treatment, 572 (67.9%) and 108 (12.8%) participants of the AILDR cohort were on antifibrotic medications and immunosuppressants respectively. There were a total of 35.6% ( n = 300) IPF patients on pirfenidone and 40.4% ( n = 340) on nintedanib in AILDR. Only 146 (23%) of the AIPFR cohort were receiving antifibrotics. Of newly registered patients in 2016 (n = 18), 2020 ( n = 71) and 2023 ( n = 151), 50.0%, 18.3% and 15.2% respectively had received immunosuppressive therapy.

Conclusion

Baseline demographics from the IPF cohorts for both AILDR and AIPFR are largely comparable, with increasing antifibrotic and decreasing use of immunosuppressants since 2016. Immunosuppressive therapy in IPF remains relatively higher than expected despite guideline recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesIdiopathic Pulmonary FibrosisImmunosuppressive AgentsAntifibrotic AgentsHumansMaleFemaleAgedAustraliaMiddle AgedAustralasiaIndolesPyridonesCohort Studies

Stichwörter der Autor:innen

Australasian interstitial lung disease registryAustralian Idiopathic pulmonary fibrosis registryIdiopathic pulmonary fibrosisbaseline characteristicstreatment profile

Substanzen

Immunosuppressive AgentsAntifibrotic AgentsIndolesPyridonespirfenidonenintedanib

Autor:innen und Institutionen

  • Department of Respiratory and Sleep Medicine, Box Hill Hospital, Melbourne, Victoria, Australia.
  • Faculty of Medicine and Health, Monash University, Melbourne, Victoria, Australia.
  • Department of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Victoria, Australia.
  • Department of Respiratory and Sleep Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Michelle Chee, Samantha Ellis, Benjamin Kwan, Vidya Navaratnam, Alan Teoh

Förderung

  • Centre of Research Excellence in Pulmonary Fibrosis
  • Australasian Interstitial Lung Disease Registry
  • Australian Idiopathic Pulmonary Fibrosis Registry
  • CSRD VA
  • NHMRC
  • Boehringer Ingelheim International GmbH
  • Roche and Bristol Myers Squibb
  • Lung Foundation Australia

Zitieren

APA

Chee, M., Khor, Y. H., Jackson, D., Cooper, W., D'Costa, J., de Boer, S., Edwards, A., Ellis, S., Gabbay, E., Gallagher, H., Glaspole, I., Goh, N., Grainge, C., Hopkins, P., Keir, G., Kwan, B., Mackintosh, J., Moodley, Y., Moore, I., …, & AILDR Steering Committee (2026). Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry. Internal Medicine Journal. https://doi.org/10.1111/imj.70490

Vancouver

Chee M, Khor YH, Jackson D, Cooper W, D'Costa J, de Boer S, et al. Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry. Internal Medicine Journal. 2026. doi:10.1111/imj.70490

BibTeX
@article{Chee2026,
  author = {Chee, Michelle and Khor, Yet Hong and Jackson, Dan and Cooper, Wendy and D'Costa, Jason and de Boer, Sally and Edwards, Adrienne and Ellis, Samantha and Gabbay, Eli and Gallagher, Henry and Glaspole, Ian and Goh, Nicole and Grainge, Christopher and Hopkins, Peter and Keir, Gregory and Kwan, Benjamin and Mackintosh, John and Moodley, Yuben and Moore, Irene and Navaratnam, Vidya and Ong, Chong and Reynolds, Paul and Royals, Karen and Teoh, Alan and Troy, Lauren and Veitch, Elizabeth and Wilsher, Margaret and Wrobel, Jeremy and Zappala, Chris and Corte, Tamera and Thien, Francis and AILDR Steering Committee, AILDR Steering Committee},
  title = {Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70490}
}
Kostenlos starten →